Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives $7.00 Consensus PT from Analysts

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has earned an average rating of “Moderate Buy” from the six ratings firms that are covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $5.50.

SGMO has been the topic of a number of recent research reports. Truist Financial upgraded shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a research note on Friday, December 13th. Wells Fargo & Company cut their price objective on Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating for the company in a research report on Tuesday. StockNews.com lowered shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 24th. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Sangamo Therapeutics in a report on Thursday. Finally, Jefferies Financial Group lowered their target price on shares of Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating for the company in a report on Tuesday.

Institutional Investors Weigh In On Sangamo Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Cubist Systematic Strategies LLC acquired a new stake in shares of Sangamo Therapeutics in the 2nd quarter worth about $67,000. Meritage Portfolio Management boosted its position in shares of Sangamo Therapeutics by 8.6% during the third quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 6,740 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in Sangamo Therapeutics during the second quarter worth $89,000. XTX Topco Ltd lifted its stake in Sangamo Therapeutics by 167.8% during the 3rd quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock valued at $90,000 after acquiring an additional 64,981 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in Sangamo Therapeutics by 55.4% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock worth $94,000 after acquiring an additional 38,850 shares during the last quarter. 56.93% of the stock is owned by institutional investors.

Sangamo Therapeutics Trading Up 10.8 %

NASDAQ SGMO opened at $1.13 on Tuesday. The stock’s 50-day moving average price is $2.14 and its two-hundred day moving average price is $1.22. The company has a market cap of $235.77 million, a PE ratio of -1.51 and a beta of 1.15. Sangamo Therapeutics has a 1 year low of $0.30 and a 1 year high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.07. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. The company had revenue of $49.41 million for the quarter, compared to analyst estimates of $26.55 million. During the same quarter in the prior year, the business posted ($0.34) EPS. Research analysts forecast that Sangamo Therapeutics will post -0.46 EPS for the current fiscal year.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.